{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:47:10Z","timestamp":1793450830141,"version":"4.5.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>Anticoagulation with unfractionated heparin remains the most common therapy used to prevent circuit thrombosis during extracorporeal membrane oxygenation, but no consensus exists on the optimal method or targets for heparin monitoring. From 2015 to 2018, we switched from monitoring heparin during extracorporeal membrane oxygenation using activated clotting times to anti-Xa heparin activity assays. This study describes the transition from activated clotting time to anti-Xa heparin activity assay monitoring and the associated clinical changes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Design:<\/jats:title>\n            <jats:p>Retrospective analysis at single institution.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Setting:<\/jats:title>\n            <jats:p>Referral Children\u2019s Hospital.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients:<\/jats:title>\n            <jats:p>A total of 145 pediatric patients over 152 extracorporeal membrane oxygenation runs using 206 extracorporeal membrane oxygenation circuits.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Anticoagulation protocol quality improvement.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Measurements and Main Results:<\/jats:title>\n            <jats:p>From 2015 to 2018, heparin monitoring during extracorporeal membrane oxygenation changed from hourly activated clotting time to anti-Xa heparin activity assay every 6 hours with an associated 75% reduction in the circuit changes per extracorporeal membrane oxygenation day. Over the 4 years, patients with an average anti-Xa heparin activity assay of at least 0.25 U\/mL showed a 59% reduction in circuit changes per extracorporeal membrane oxygenation day compared with less than 0.15 U\/mL. In addition to its association with reduced circuit changes, anti-Xa heparin activity assay monitoring was also associated with reduced heparin dose changes per day from 11\u2009\u00b1\u20094 to 2\u2009\u00b1\u20091 (<jats:italic toggle=\"yes\">p<\/jats:italic> &lt; 0.001), smaller heparin dose changes (less variation in dose), and reduced diagnostic phlebotomy volumes from 41\u2009\u00b1\u20096 to 25\u2009\u00b1\u200911\u2009mL\/day (<jats:italic toggle=\"yes\">p<\/jats:italic> &lt; 0.001). The number of patients with reported bleeding decreased from 69% using activated clotting time to 51% (<jats:italic toggle=\"yes\">p<\/jats:italic> = 0.03). Transfusion rates did not change.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Over 4 years, we replaced the activated clotting time assay with the anti-Xa heparin activity assay for heparin monitoring during extracorporeal membrane oxygenation. Minimum anti-Xa heparin activity assay levels of 0.25 U\/mL were associated with reduced circuit changes. Further studies are needed to determine the optimum anti-Xa heparin activity assay therapeutic range during extracorporeal membrane oxygenation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ccm.0000000000004615","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:21:06Z","timestamp":1601511666000},"page":"e1179-e1184","source":"Crossref","is-referenced-by-count":24,"title":["Conversion From Activated Clotting Time to Anti-Xa Heparin Activity Assay for Heparin Monitoring During Extracorporeal Membrane Oxygenation*"],"prefix":"10.1097","volume":"48","author":[{"given":"Cristina A.","family":"Figueroa Villalba","sequence":"first","affiliation":[{"name":"Seattle Children\u2019s Hospital, University of Washington, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas V.","family":"Brogan","sequence":"additional","affiliation":[{"name":"Seattle Children\u2019s Hospital, University of Washington, Seattle, WA."},{"name":"Department of Pediatrics, University of Washington, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Michael","family":"McMullan","sequence":"additional","affiliation":[{"name":"Seattle Children\u2019s Hospital, University of Washington, Seattle, WA."},{"name":"Division of Cardiothoracic Surgery, Department of Surgery, University of Washington, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Yalon","sequence":"additional","affiliation":[{"name":"Seattle Children\u2019s Hospital, University of Washington, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Ian","family":"Jordan","sequence":"additional","affiliation":[{"name":"Seattle Children\u2019s Hospital, University of Washington, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne L.","family":"Chandler","sequence":"additional","affiliation":[{"name":"Seattle Children\u2019s Hospital, University of Washington, Seattle, WA."},{"name":"Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,10,1]]},"reference":[{"key":"R1-20230812","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1164\/rccm.201609-1945OC","article-title":"Factors associated with bleeding and thrombosis in children receiving extracorporeal membrane oxygenation.","volume":"196","author":"Dalton","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"R2-20230812","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jcrc.2017.02.014","article-title":"Anticoagulation practices and the prevalence of major bleeding, thromboembolic events, and mortality in venoarterial extracorporeal membrane oxygenation: A systematic review and meta-analysis.","volume":"39","author":"Sy","year":"2017","journal-title":"J Crit Care"},{"key":"R3-20230812","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.thromres.2019.05.006","article-title":"Routine laboratory measures of heparin anticoagulation for children on extracorporeal membrane oxygenation: Systematic review and meta-analysis.","volume":"179","author":"Padhya","year":"2019","journal-title":"Thromb Res"},{"key":"R4-20230812","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1097\/PCC.0000000000000107","article-title":"Age-based difference in activation markers of coagulation and fibrinolysis in extracorporeal membrane oxygenation.","volume":"15","author":"Hundalani","year":"2014","journal-title":"Pediatr Crit Care Med"},{"issue":"Suppl 1","key":"R5-20230812","doi-asserted-by":"crossref","first-page":"S336","DOI":"10.1111\/jth.12963","article-title":"Extracorporeal life support: The precarious balance of hemostasis.","volume":"13","author":"Annich","year":"2015","journal-title":"J Thromb Haemost"},{"key":"R6-20230812","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1097\/PCC.0000000000002104","article-title":"Bleeding and thrombosis with pediatric extracorporeal life support: A roadmap for management, research, and the future from the Pediatric Cardiac Intensive Care Society: Part 2.","volume":"20","author":"Penk","year":"2019","journal-title":"Pediatr Crit Care Med"},{"key":"R7-20230812","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3389\/fmed.2018.00361","article-title":"Coagulation and bleeding management in pediatric extracorporeal membrane oxygenation: Clinical scenarios and review.","volume":"5","author":"Hensch","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"R8-20230812","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1097\/PCC.0b013e31827127e4","article-title":"Variability in anticoagulation management of patients on extracorporeal membrane oxygenation: An international survey.","volume":"14","author":"Bembea","year":"2013","journal-title":"Pediatr Crit Care Med"},{"key":"R9-20230812","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/MAT.0b013e318279854a","article-title":"Anticoagulation monitoring during pediatric extracorporeal membrane oxygenation.","volume":"59","author":"Bembea","year":"2013","journal-title":"ASAIO J"},{"key":"R10-20230812","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/MAT.0000000000000993","article-title":"Monitoring hemostasis during extracorporeal life support.","volume":"66","author":"Saifee","year":"2020","journal-title":"ASAIO J"},{"key":"R11-20230812","doi-asserted-by":"crossref","first-page":"e363\u2013e371","DOI":"10.1097\/PCC.0b013e31825b582e","article-title":"Activated partial thromboplastin time is a better trending tool in pediatric extracorporeal membrane oxygenation.","volume":"13","author":"Maul","year":"2012","journal-title":"Pediatr Crit Care Med"},{"key":"R12-20230812","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1177\/0267659114524264","article-title":"Evaluation of the activated clotting time and activated partial thromboplastin time for the monitoring of heparin in adult extracorporeal membrane oxygenation patients.","volume":"29","author":"Atallah","year":"2014","journal-title":"Perfusion"},{"key":"R13-20230812","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.cll.2014.06.014","article-title":"Management of anticoagulation and hemostasis for pediatric extracorporeal membrane oxygenation.","volume":"34","author":"Saini","year":"2014","journal-title":"Clin Lab Med"},{"key":"R14-20230812","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1160\/TH06-05-0290","article-title":"Monitoring unfractionated heparin with the aPTT: Time for a fresh look.","volume":"96","author":"Eikelboom","year":"2006","journal-title":"Thromb Haemost"},{"key":"R15-20230812","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1080\/17474086.2017.1345306","article-title":"Therapeutic monitoring of unfractionated heparin - trials and tribulations.","volume":"10","author":"Baluwala","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"R16-20230812","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/00003246-200204000-00007","article-title":"Frequent development of lupus anticoagulants in critically ill patients treated under intensive care conditions.","volume":"30","author":"Wenzel","year":"2002","journal-title":"Crit Care Med"},{"key":"R17-20230812","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1309\/AJCPGVD62LKKVDLH","article-title":"Evaluation of heparin assay for coagulation management in newborns undergoing ECMO.","volume":"134","author":"Khaja","year":"2010","journal-title":"Am J Clin Pathol"},{"key":"R18-20230812","first-page":"170","article-title":"Hemostasis changes during veno-venous extracorporeal membrane oxygenation for respiratory support in adults.","volume":"82","author":"Panigada","year":"2016","journal-title":"Minerva Anestesiol"},{"key":"R19-20230812","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/01.mat.0000247777.65764.b3","article-title":"Assessing heparin dosing in neonates on venoarterial extracorporeal membrane oxygenation.","volume":"53","author":"Nankervis","year":"2007","journal-title":"ASAIO J"},{"key":"R20-20230812","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/0267659117720494","article-title":"Coagulation monitoring correlation with heparin dose in pediatric extracorporeal life support.","volume":"32","author":"Moynihan","year":"2017","journal-title":"Perfusion"},{"key":"R21-20230812","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.athoracsur.2006.09.054","article-title":"Anticoagulation and pediatric extracorporeal membrane oxygenation: Impact of activated clotting time and heparin dose on survival.","volume":"83","author":"Baird","year":"2007","journal-title":"Ann Thorac Surg"},{"key":"R22-20230812","doi-asserted-by":"crossref","first-page":"e175\u2013e182","DOI":"10.1097\/PCC.0000000000000101","article-title":"Unfractionated heparin activity measured by anti-factor Xa levels is associated with the need for extracorporeal membrane oxygenation circuit\/membrane oxygenator change: A retrospective pediatric study.","volume":"15","author":"Irby","year":"2014","journal-title":"Pediatr Crit Care Med"},{"key":"R23-20230812","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1213\/ANE.0000000000000115","article-title":"Extracorporeal membrane oxygenation in the adult: A review of anticoagulation monitoring and transfusion.","volume":"118","author":"Esper","year":"2014","journal-title":"Anesth Analg"},{"key":"R24-20230812","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/MAT.0000000000000811","article-title":"Impact of anticoagulation and circuit technology on complications during extracorporeal membrane oxygenation.","volume":"65","author":"Niebler","year":"2019","journal-title":"ASAIO J"},{"key":"R25-20230812","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1051\/ject\/201850149","article-title":"Use of thromboelastography to predict thrombotic complications in pediatric and neonatal extracorporeal membranous oxygenation.","volume":"50","author":"Henderson","year":"2018","journal-title":"J Extra Corpor Technol"},{"key":"R26-20230812","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/MAT.0000000000000204","article-title":"Anti-Xa directed protocol for anticoagulation management in children supported with extracorporeal membrane oxygenation.","volume":"61","author":"O\u2019Meara","year":"2015","journal-title":"ASAIO J"},{"key":"R27-20230812","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/aor.13467","article-title":"Interference in the anti-Xa heparin activity assay due to hemolysis and icterus during pediatric extracorporeal life support.","volume":"43","author":"Khan","year":"2019","journal-title":"Artif Organs"}],"container-title":["Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCM.0000000000004615","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T09:19:22Z","timestamp":1691831962000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCM.0000000000004615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/ccm.0000000000004615","relation":{},"ISSN":["0090-3493"],"issn-type":[{"value":"0090-3493","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,1]]}}}